Live Breaking News & Updates on Organ Stanley On Covid

Indian equities are likely to outperform their emerging market (EM) peers in 2021, says the latest report by Morgan Stanley and bets on domestic cyclical stocks followed by rate sensitives. The research and broking house, however, has kept its December 2021 target for the S&P BSE Sensex unchanged at 55,000 levels (base case; 50 per cent probability) for now – an upside of around 10 per cent from the current levels.
“Our unchanged BSE Sensex target of 55,000. This level implies that the BSE Sensex would trade at a forward P/E multiple of 17.5x and a trailing P/E of 21.2, ahead of the 25-year average of 19.7x. This premium over the historical average reflects a higher confidence in the medium-term growth cycle in India. We are overweight on India in a global emerging markets (GEMs) context,” wrote Ridham Desai, head of India research and India equity strategist at Morgan Stanley in a coauthored report with Sheela Rathi and Nayant Parekh. ....

Yuvika Singhal , Shubhada Rao , Chris Wood , Sheela Rathi , Nayant Parekh , Ridham Desai , Vivek Kumar , Morgan Stanley , Quanteco Research , Communication Services , Consumer Discretionary , Consumer Staples , Organ Stanley Sensex Estimate , Organ Stanley Eps Estimate , Organ Stanley On Covid , Quanteco Research , Ensex Target 2021 , Organ Stanley Sensex Target 2021 , Morgan Stanley Ridham Desai , Morgan Stanley , யுவிகா சிங்கால் , சுபாதா ராவ் , கிறிஸ் மரம் , ஷீலா ரதி , ரிடம் தேசாய் , விவேக் குமார் ,